It's Rare Disease Week and Rare Disease Day is Feb. 28, both of which are aimed at highlighting the difficulty and costliness of treating rare conditions.
Modern Healthcare's CEO Power Panel survey indicates healthcare leaders still fear unbridled drug costs and wonder if the industry has reached a breaking point.
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses. Preliminary figures released Thursday suggest the vaccine is 36% effective overall in preventing flu illness severe enough to send a patient to the doctor's office.
Providers should not expect to see lower drug prices from a potential Walgreens Boots Alliance and AmerisourceBergen Corp. deal, analysts say.
Proteus makes digital sensors for pills that track medication adherence, including in Abilify Mycite, the first of such drugs to receive FDA approval.
President Donald Trump has tapped deputy White House chief of staff Jim Carroll to serve as the administration's next drug czar, making him the most public face of the administration's efforts to fight the opioid epidemic.
OxyContin has long been the world's top-selling opioid painkiller, bringing in billions in sales for privately held Purdue Pharma. Now, the company said it will stop marketing opioid drugs to doctors.
The White House's Council of Economic Advisers has recommended easing government regulations to lower drug prices and reinforce the Food and Drug Administration's push to spur competition through expedited approvals.
A pharmacist has been sentenced to eight years in prison for his role in a deadly 2012 meningitis outbreak that killed 76 people and made nearly 800 seriously ill. The meningitis infection was traced to contaminated steroid injections given mostly to people with back pain.
Alex Azar's job hop from drugmaker Eli Lilly to the Trump administration reflects ever-deepening ties between the pharmaceutical industry and the federal government.
Fans of the dystopian Netflix drama Black Mirror are annoyed by a major medical mix-up this season.
The new health system-led generic-drug company sent a shockwave through the healthcare industry, but experts warned that it would take plenty of time and capital to ultimately lower drug prices and mitigate shortages.